They further demonstrated that standard treatment can reduce differential potential while increase regulon activity, and CXCR4 may represent an attractive therapeutic target, since clinical trials have already tested CXCR4 antagonist for relapsed myeloma [148] and use for other clinical applications [149]. The gene discussed is CXCR4; the disease is plasma cell myeloma.